Duke Street Bio
  • About
  • Science
    • R&D Programs
    • Publications
    • News
  • People
  • Pipeline
  • Contact
Select Page
Next Gen PARP1 & PARP7 inhibitor programmes

Next Gen PARP1 & PARP7 inhibitor programmes

by Barry McGuinness | May 22, 2022 | Drug discovery programmes, Immuno-oncology

Duke Street Bio – DDR & IO biotech emerges from stealth mode to discuss its next generation PARP1 and PARP7 inhibitor programmes Since 2019 the management team behind small molecule immuno-oncology biotech IOmet Pharma, acquired by Merck & Co (known as...

Recent Posts

  • Duke Street Bio Announces Appointment of Head of Clinical Operations
  • Duke Street Bio Announces Appointment of Chief Medical Officer
  • Next Gen PARP1 & PARP7 inhibitor programmes

Recent Comments

    © Duke Street Bio Ltd | hello@dukesb.com | Privacy